Skip to main content
. 2020 Jun 10;15(6):e0234493. doi: 10.1371/journal.pone.0234493

Fig 3. Blockage of carnitine palmitoyl transferase 1A (CPT1A) by etomoxir in a rat experimental autoimmune encephalomyelitis (EAE) model.

Fig 3

Rats were subjected to myelin basic protein (MBP)-induced EAE and treated either with etomoxir (1 mg/kg/day s.c., n = 16.) or placebo (n = 26). Etomoxir-treated rats exhibited significantly lower disease scores at day 11 compared to rats receiving placebo analyzed by a two-way ANOVA with Sidak’s multiple comparisons post hoc tests (a). The results from the two-way ANOVA with Sidak’s multiple comparisons post hoc test showed significantly higher body weight in the rats subjected to etomoxir treatment as compared to placebo-treated animals at day 9, 10 and 11 (b). Statistically significant differences between etomoxir and placebo treated rats were observed for maximum disease score and disease onset (unpaired t test) (c). Etomoxir treatment resulted in 25% of the rats showing normal behavioral scores compared to 0% after placebo treatment analyzed by a Fisher´s exact test (c). Data are represented as mean ± SEM. Number of asterisks indicates the level of statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001).